Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe?

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Lipid-lowering therapy (LLT) reduces atherosclerotic cardiovascular events in chronic kidney disease (CKD) patients.
• The benefit of LLT appears less pronounced in patients on dialysis compared to pre-dialysis CKD.
• Non-atherosclerotic cardiovascular disease is more prevalent in end-stage renal disease, complicating LLT's role.

Purpose of the Study:

• To review recent trials of LLT in CKD, focusing on Ezetimibe.
• To discuss the implications of LLT findings for CKD patient management.
• To evaluate the evidence supporting Ezetimibe's efficacy in CKD.

Main Methods:

• Review of recent clinical trials on LLT in CKD.
• Analysis of data from the SHARP study (simvastatin and ezetimibe).
• Examination of surrogate endpoint data and potential off-target effects of Ezetimibe.

Main Results:

• LLT reduces cardiovascular events but not mortality in CKD.
• Ezetimibe effectively lowers cholesterol, but lacks independent evidence for reducing cardiovascular events.
• SHARP study provided evidence for combined simvastatin and ezetimibe in CKD.

Conclusions:

• The role of LLT in CKD is less clear than in the general population.
• Ezetimibe's benefit in CKD is primarily demonstrated through cholesterol reduction, with contentious surrogate endpoint data.
• Further cardiovascular outcome data are needed to validate Ezetimibe's use in CKD.